Cargando…

Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors

SIMPLE SUMMARY: Ovarian cancer (OC) is known for its poor prognosis, due to the absence of reliable biomarkers and its late diagnosis, since the early-stage disease is almost asymptomatic. Lipid metabolism plays an important role in OC progression due to the development of omental metastasis in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacome Sanz, Dafne, Raivola, Juuli, Karvonen, Hanna, Arjama, Mariliina, Barker, Harlan, Murumägi, Astrid, Ungureanu, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345177/ https://www.ncbi.nlm.nih.gov/pubmed/34359627 http://dx.doi.org/10.3390/cancers13153727

Ejemplares similares

Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention
por: Raivola, Juuli, et al.
Publicado: (2022)

Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness
por: Karvonen, Hanna, et al.
Publicado: (2020)

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
por: Murumägi, Astrid, et al.
Publicado: (2021)

ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity
por: Piki, Emilia, et al.
Publicado: (2023)

New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome
por: Raivola, Juuli, et al.
Publicado: (2022)

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma
por: Kohtamäki, Laura, et al.
Publicado: (2021)

Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways
por: Karvonen, Hanna, et al.
Publicado: (2019)

Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma
por: Murumägi, Astrid, et al.
Publicado: (2022)

Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling
por: Raivola, Juuli, et al.
Publicado: (2019)

Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
por: T. Virtanen, Anniina, et al.
Publicado: (2019)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition
por: Cai, Hua, et al.
Publicado: (2023)

Membrane-Type-3 Matrix Metalloproteinase (MT3-MMP) Functions as a Matrix Composition-Dependent Effector of Melanoma Cell Invasion
por: Tatti, Olga, et al.
Publicado: (2011)

Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain
por: Raivola, Juuli, et al.
Publicado: (2018)

Current development of the second generation of mTOR inhibitors as anticancer agents
por: Zhou, Hong-Yu, et al.
Publicado: (2012)

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
por: Brunen, Diede, et al.
Publicado: (2016)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

The Role and Application of Sirtuins and mTOR Signaling in the Control of Ovarian Functions
por: Sirotkin, Alexander V.
Publicado: (2016)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

mTOR Controls Ovarian Follicle Growth by Regulating Granulosa Cell Proliferation
por: Yu, James, et al.
Publicado: (2011)

Analysis of mTOR Inhibition-Involved Pathway in Ovarian Clear Cell Adenocarcinoma
por: Harasawa, Makiko, et al.
Publicado: (2011)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
por: Heinzen, Dennis, et al.
Publicado: (2019)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

mTOR and Tumor Cachexia
por: Duval, Adrian P., et al.
Publicado: (2018)

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

mTOR in Human Diseases
por: Dormond, Olivier
Publicado: (2019)

Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway
por: Yuan, Lingqin, et al.
Publicado: (2015)

Oridonin inhibits metastasis of human ovarian cancer cells by suppressing the mTOR pathway
por: Wang, Ye, et al.
Publicado: (2018)

mTOR inhibitors and risk of ovarian cysts: a systematic review and meta-analysis
por: Parazzini, Fabio, et al.
Publicado: (2021)

Inhibition of apoptosis through AKT-mTOR pathway in ovarian cancer and renal cancer
por: Chen, Hongrun, et al.
Publicado: (2023)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o86c1m6ut3gdmovb860u3vnr0m